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1. Introduction 
Locally advanced diseases accounting for most HNSCC have a poor prognosis. The main 
reason for this is that corresponding symptoms of HNSCC are not always obvious or 
ignored by patients at early stage, which is mostly reflected by the fact that more than 2/3 
HNSCC patients present with stage III/IV disease (AL-Sarraf, 1987; Argiris, 2008). 
Patients characterized with advanced HNSCC are subjected to worse prognosis than those 
with confined disease, exhibiting 5-year survival of 10-40%, cure rate of 30% and median 
survival time of 6-10 months (Argiris, 2008; Vokes et al, 1993; Cohen et al, 2004). Our 
recent study in a large series (X. Li et al, 2009) demonstrated that overall survival rates of 
patients with distant metastases in clinic were 56.8% at 1 year, 9.1% at 3 years, and 6.8% at 
5 years, respectively. In addition, traditional treatment related morbidities could 
negatively influence quality life of patients, which involves loss of speech, permamant 
tracheostomy or gastrostomy dependence, dysphagia and other systematic side effects. 
Therefore, it is necessary to seek novel strategies to cure advanced HNSCC aiming at 
organ preservation, prevention of metastases as well as second malignancies and 
improvement in quality of life.  
2. Necessities for adjuvant therapies in HNSCC 
Surgical ablation plays a major role in the management of locoregional diseases of HNSCC. 
At early stage of HNSCC, current novel surgical alternatives, such as laser surgery, can 
achieve curable effects for 5-year survival rate of 80% even without prominent functional 
detriments. However, many tumors in the advanced stage are inoperable either due to the 
invasion of some major structures by tumor or due to the unfavorable general conditions of 
patients. Moreover, even with very skillful surgeons, some tumors remain after surgical 
resection, leading to postoperative recurrence if additional complimentary treatment is not 
carried out. In tumors with regional lymph node metastasis, extracapsular nodal spread 
always implicates poor prognosis even after a comprehensive neck dissection. For these 
conditions, adjuvant therapies such as radiotherapy, chemotherapy and chemoratiation are 
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due to undertake to increase the chance of cure or to prolong duration of survival of 
advanced cases.  
2.1 Traditional adjuvant therapies improve outcome of advanced HNSCC  
The participation of radiotherapy improved effects of surgery alone. In 2008, Cancer journal 
(Lavaf et al, 2008) reported a large-scale analysis with regard to effects of combined surgery 
and radiotherapy on survival of patients with lymph node-positive HNSCC patients. In 
8795 patients meeting the inclusion criteria, 54.9% of 3-year overall survival and 43.2% of 5-
year overall survival for adjuvant therapy could be gotten compared with 44.4% and 33.4% 
for surgery alone. More recently, a new analysis with large series (Shrime, 2010) reported 
that postoperative radiotherapy improved 5-year overall survival rate in patients with T1-
2N1 oral squamous carcinoma (41.4% for surgery alone vs. 54.2% for surgery plus 
radiotherapy). Although statistically significant, slight improvement in survival has to 
indicate the limitation of single radiotherapy addition, which appeals the need of 
chemotherapy in the management of advanced HNSCC. In 2009, the journal of The Lancet 
Oncology published a 10-year follow-up report of a trial for chemoradiotherapy for locally 
advanced head and neck cancer conducted by The UK Head and Neck (UKHAN) cancer 
group (Tobias et al, 2009). In this follow-up analysis, patients who did not undergo previous 
surgery benefited from scheduled simultaneous addition of chemicals to radiotherapy, 
exhibiting 4-7 years in the median overall survival. However, the median overall survival of 
patients undergoing surgery was still higher without substantial benefit from chemotherapy 
alone. Furthermore, sequent toxicity reactions, such as mucositis and xerostomia, are due to 
occur. All these findings suggest that the effects of traditional chemicals in treating the 
HNSCC are limited due to their unspecific hallmarks. 
2.2 Limitations of traditional adjuvant chemoradiation therapies 
As is known, HNSCC depend on many intrinsic or extrinsic factors to protect against 
traditional chemotherapeutic agents, such as cisplatin and 5- fluorouracil. As evidenced by 
clinical observations, HNSCC possesses a decreased sensitivity and increased resistance to 
chemo- and radiotherapy, giving rise to a poor tumor control efficacy of these treatment 
modalities. This situation is mostly reflected by the fact that many HNSCCs (including 
primary and recurrent carcinomas) have less or no response to the adopted treatment 
regimens in the course of chemotherapy and/or radiotherapy. For this reason, some tumors 
regenerate or relapse following a short- or long-term paracmasis during which time the 
tumor bulk contracts or even disappears visually in response to therapy. Therefore, chemo- 
and radiotherapeutic resistance and post-treatment relapse has been always a puzzling 
problem that needs to be solved urgently.  
3. Role of hypoxia in therapeutic resistance in HNSCC 
The mechanisms underlying resistance to chemo- and/or radiotherapy by HNSCC are very 
complicated. Among various factors that are associated with therapeutic resistance in 
HNSCC, hypoxic microenvironment resulting from hypoxia in local cancer lesions is 
thought to be important one. It has been demonstrated that, most solid tumors have a lower 
pressure of oxygen (PO2) compared with normal tissues from which they originate. Hypoxia 
occurs due to rapid proliferation of cells and/or insufficient supplies of blood. The latter 
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attributes to poor drugs delivery, leading to a common cause of chemoresistance. In 
addition, activated intrinsic pathways within tumor cells contribute to comprehensive radio- 
and chemo-resistance under hypoxic condition. In this section, we will focus on these 
intrinsic responses underlying resistance under hypoxia.  
3.1 The general responses to hypoxia in tumor cells 
General responses of tumor cells under hypoxia include translation inhibition, paradoxical 
translation and genetic instability. ATP defect caused by hypoxia invokes global translation 
inhibition for maintaining energy homeostasis. However, paradoxically, tumor cells activate 
some factors which are always unexpressed under normal conditions for adaptation to 
hypoxic stress. These proteins act as mediators of PH and metabolism, as well as function to 
propagate therapeutic resistance. In the long run, hypoxia-induced reactive oxygen species 
(ROS) and/or defective DNA repair induce mutagenesis of tumor cells to confer selection of 
heterogeneous population with hypoxia tolerance (see Fig. 1). 
 
Fig. 1. General responses to hypoxia of tumor. Hypoxic tumor cells inhibit translation via 
mTOR pathways as well as UPR for energy homeostasis. Meanwhile paradoxically, they 
express some factors, such as HIF-1ǂ and GRP78, to degrade nonfunctioning protein, 
regulate PH and counter apoptosis. These factors also act as resistance to therapy and 
metastasis. Hypoxia induced mutagenesis select clonal subset characterized with aggressive 
phenotypes, which confer more malignant biological behaviors including therapeutic 
resistance. 
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3.2 Hypoxia-related translation inhibition  
3.2.1 The mammalian target of rapamycin (mTOR) pathways 
Protein synthesis is processed as a result of energy-consumption. To date, emerging data 
have evidenced that inhibition of translation is an important category of cellular hypoxic 
tolerance, and the process occurs during the initial step of translation. The initiation of 
translation involves two components, the eukaryotic initiation factor 4F (eIF4F) as well as 
43S preinitiation complex. The former consists of the cap binding protein eIF4E, a 
scaffolding protein eIF4G and an ATP-dependent helicase eIF4A (RNA helicase activity), 
among which eIF4E and eIF4G mostly participate in the regulation of initiation of 
translation. Under nutrient and/or oxygen repletion, mTOR phosphorylates eukaryotic 
initiation factor 4E binding protein 1 (4EBP1) that has a high affinity with eIF4E to low the 
affinity. Together with eIF4G, released eIF4E contributes to assembly of eIF4F complex that 
binds to the 5’m7GpppN cap structure of mRNA to facilitate the recruitment of 43S 
preinitiation complex that includes the 40S ribosomal subunit and the ternary complex 
(eIF2-GTP and the methionine-loaded initiator tRNA) for the start of translation initiation. 
The ribosomal constituents of preinitiation complex scan though the 5′ untranslated region 
(5'UTR) until the AUG initiation codon is recognized. Sequently, the 60S ribosomal subunit 
joins to form 80S ribosome for the elongation of translation. Lots of recent reports have 
implicated that hypoxia can disturb the process above via hypoxic activation of the tuberous 
sclerosis protein 1 (TSC1)–TSC2 complex-mediated downregulation of mTOR.  Thereby, 
corresponding expressions of translation initiation-related proteins, such as phosphorylated 
4EBP1 and eIF4F, other mTOR-mediated targets and S6 protein kinases (S6K 1 and 2), all of 
which also function in translation, would be inactivated accordingly. In addition, hypoxia 
also interferes with formation of preinitiation complex to inhibit translation via PERK-
mediated cascade of unfolded protein responses.  
3.2.2 Unfolded protein responses (UPR) 
UPR is an evolutionary conserved protective response to microenvironment stress. Because 
of abnormal vascular structure and aggressive cellular growth, hypoxia and glucose 
starvation always occur in tumor microenvironment, resulting in defective usage of energy 
in response to accumulation of many unfolded protein in endocytoplasmic reticulum (ER). 
Tumor cells must adapt to this stress though inhibiting mRNA and protein synthesis as well 
as degrading excessive useless protein, which is executed though activation of UPR. 
Glucose-regulated protein 78 (GRP78/BiP) is the core regulator in ER-stress and 
overexpressed in most tumor as a predictor of poor prognosis. Routinely, GRP78 binds to 
ER-stress sensors, IRE1ǂ (inositol-requiring 1 alpha), PERK (double-strand RNA-activated 
protein kinase-like ER kinase), and ATF6 (activating transcription factor 6), to inactivate 
their downstream targets. Once ER-stress occurs, the role of GRP78 is shifted towards that of 
a chaperone. After dissociation, GRP78 handles unfolded protein to facilitate degradation 
and binds to Ca2+ to inhibit apoptosis. Importantly, the dissociation activates these integral 
ER membrane sensors PERK, IRE-1 and ATF6. Activated PERK phosphorylates eukaryotic 
initiation factor 2 subunit ǂ (eIF2ǂ), leading to either inhibition of global protein 
translational attenuation or paradoxical expression of the transcription factor 4 (ATF4) that 
immediately blocks eIF2ǂ phosphorylation and sequently encodes genes upregulating 
stress-adaptive factors, such as GRP78 and hypoxia inducible factors (HIFs). UPR also 
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includes IRE-1 and ATF6 arms. Activated IRE-1 serves as an endoribonuclease to remove a 
26 nucleotide intron from X-box binding protein 1 (XBP1) pre-mRNA. The resulting XBP1 
protein by spliced XBP1 mRNA can activate lots of ER chaperones and enzymes to remove 
mis/unfolded protein and help ER-localized protein maturation as well as ER-associated 
degradation. Similar with XBP1, ATF6 needs cleavage for its activation. Briefly, upon UPR 
activation, ATF6 is transmitted from ER to Golgi apparatus where ATF6 completes its 
splicing process. Subsequently, cleaved ATF6 also activates target genes functioning in 
protein degradation and upregulation of molecular chaperones. As a matter of fact, their 
functions and target genes overlap one another. Overall, these sensors play a critical role in 
inhibition of mRNA and protein synthesis and upregulation of stress-adaptive factors. As a 
final step, unfolded protein is transported to cytoplasm and degraded via ubiquitin-
proteasome pathway (UPP) or autophagy. To our understanding, UPR is a double-edged 
sword. On the one hand, PERK--eIF2a-ATF4 pathway is a dominant UPR arm offering 
survival advantage under hypoxia. On the other hand, once severe stress persists, UPR will 
induce ER-stress-relared cell death (apoptosis, autophagy associated programmed death or 
necrosis). To date, GADD153/CHOP induced by ATF4, has been identified as a pro-
apoptosis factor that can activate cascades of caspases, mediating type I programmed cell 
death (known as apoptosis). It remains to be determined by what mechanisms the UPR 
induces autophagic death and necrosis.  
3.3 Factors expressed paradoxically under hypoxia  
3.3.1 HIF-1α 
HIFs are core factors regulating oxygen and energy supplies of the tumor bulk, by which 
tumor cells adapt to hypoxia through inducing expressions of related genes to overcome 
such an unfavorable low-oxygen condition. HIFs are members of bHLH-PAS protein family 
including HIF-ǂ and HIF-ǃ subunit, the former of which also includes HIF-1ǂ, HIF-2ǂ and 
HIF-3ǂ. Functionally, HIF-ǂ (HIF-1ǂ, HIF-2ǂ) can be stably sustained in the hypoxic niche. 
In the event of cell signaling, HIF-ǂ (HIF-1ǂ, HIF-2ǂ) and HIF-ǃ can form a heterodimer that 
binds to promoters or enhancers of target genes.  Hypoxia not only induces the expression 
of HIF-1ǂ, but also activates many specific biological effects of HIF-1ǂ gene protein, which 
functions either to acquire the tolerance to hypoxia or to commit the capability of invasion, 
metastasis and therapeutic resistance: 1) inducing expression of carbonate dehydrates 
(CAH) to maintain a stable cytoplasmic PH to promote the survival ability of cancer cells in 
response to apoptosis-inducing factors; 2) upregulating the expression of MDR gene and its 
product, P-gp, resulting in resistance to multiple chemotherapeutic agents; 3) mediating the 
overexpression and activation of DNA kinase (DNA-PK), contributing essentially to the repair 
of DNA double-strand breaks (DSBs); 4) acting as an upstream regulator of genes encoding 
vascular endothelial growth factor (VEGF) as well as some key enzymes related to glycolysis, 
responsible for angiogenesis and glycometabolism within tumors; 5) promoting expressions of 
anti-apoptosis proteins such as Survivin and XIAP to inhibit the activation of pro-apoptosis 
proteins Bax and caspases, rendering the tumor cells the ability to escape from apoptosis.   
3.3.2 Signal transducer and activator of transcription 3 (STAT3) 
STAT3 is an important factor overlapped by many intracellular signal pathways. It can be 
activated though Janus kinases (JAKs) or tyrosine kinase receptors such as EGFR. Upon 
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phosphorylation at the Tyr705 residue, p-STAT3 translocates to nucleus to bind DNA for 
inducing the transcription of downstream targets. Emerging reports have demonstrated that 
STAT3 is associated with poor prognosis in many cancers including HNSCC. STAT3 induces 
resistance to therapy in tumors via activation of anti-apoptosis factors, such as Bcl-2, Bcl-xl as 
well as Survivin and downregulation of P53. Recently, a study demonstrated that STAT3 
participates in inhibition of apoptosis caused by PIs in HNSCC (C. Li et al, 2009). Under 
hypoxia, STAT3 can be activated by ROS (Simon et al, 1998). Selvendiran et al (Selvendiran et 
al, 2009) found that STAT3 can be activated by production of ROS under 1% O2 in ovarian 
cancer. In their study, overexpressed STAT3 contributed to similar rate of proliferation as that 
under normoxia but increased drug resistance under hypoxia. Through blockage of STAT3 
using RNAi technique, ovarian tumor cells with defective expression of STAT3 exhibited 
affected proliferation as well as increased sensitivity to traditional chemotherapeutics under 
hypoxia.  In HNSCCs, STAT3 was also found to be constitutively activated and associated 
with cervical lymph node metastasis in laryngeal cancer. Silencing STAT3 gene with specific 
siRNA enhances the sensitivity of Hep-2 human laryngeal carcinoma cells to ionizing 
radiation both in vitro and in xenotransplanted mice model. (X. Li, et al, 2010a, 2010b) 
3.4 Hypoxic dynamic complication in solid tumor 
3.4.1 Category of hypoxia  
In solid tumor, hypoxia can be categorized as chronic continuing hypoxia and cyclic 
hypoxia (also called intermittent hypoxia or fluctuating hypoxia) depending on distances of 
tumor cells from the adjacent vessels. The former is incurred from the condition that tumor 
cells locating far from vessels result to diffusion-limited and relatively stable delivery of 
oxygen. On the other hand, the latter characterized by acute hypoxia/reoxygenation is 
caused by status of nearby vessels that suffer from dynamic changes in blood perfusion not 
least as a result of the abnormal vasculature and the mechanical instability of microvessel 
walls caused by proliferating tumor cells and/or circulating blood cells. With regard to 
insufficiency in blood or oxygen supply, hypoxia is classified as mild hypoxia (PO2: 1-3%), 
moderate hypoxia (PO2: 0.1-1%) and severe hypoxia (PO2: 0-0.1%) ((Koumenis & Wouters, 
2006). Additionally, in term of duration of persistent hypoxic condition, hypoxia is divided 
into acute hypoxia lasting several minutes to several hours as well as prolonged chronic 
hypoxia during which cells are exposed to hour-to-day intracellular low PO2. The complex 
nature of hypoxia and different responses to distinct hypoxia by tumor cells may explain 
why it is so difficult to antagonize hypoxia-induced therapeutic resistance in HNSCCs. 
3.4.2 Chronic versus cyclic 
In most lab experiments, there is an important difference ignored by us. That is the 
parameters of hypoxic condition selected by most investigators are usually simple and fairly 
stable. However, reoxygenation may occur during manipulation of assorted cells. To date, 
cyclic hypoxia has been less studied than chronic hypoxia. The setting of cyclic hypoxic 
condition was not consistent among various studies on cyclic hypoxia. Here we introduce 
the difference between the two as follows with special emphasis on the importance of cyclic 
hypoxia. Firstly, cyclic hypoxia confers more potential therapeutic resistance than chronic 
hypoxia. It has been demonstrated by many studies that increased expression of HIF-1ǂ 
contributes to cyclic hypoxia-induced resistance. In addition, it has been confirmed that 
chronically hypoxic tumor cells are more susceptible to ionizing radiation (IR) or DNA-
damaging drugs than acutely hypoxic tumor cells because of decreased homologous 
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recombination (HR) function, a main pathway to repair DNA double-strand breaks (DSBs) 
in the S and G2 phases of the cell cycle. Secondly, cyclic hypoxia induces an enhanced 
metastasis. It was found that mice bearing melanoma xenografts exposed to cyclic hypoxia 
suffered from increased incidence of pulmonary metastases (Rofstad et al, 2010). 
Furthermore, tumor cells treated by cyclic hypoxia up-regulates the expression of VEGF-A, 
the ligand of VEGFR-1 on bone marrow derived cells confirmed to form ‘‘premetastasis 
niche’’. Therefore, induction of VEGF-A by hypoxia may be an important promoter of 
metastasis. Thirdly, cyclic hypoxia enhances metabolism of Tirapazimine (TPZ), an agent 
with specific hypoxic cytotoxicity, by intratumoral vessels adjacent to the populated tumor 
cells, which attenuates the effects of TPZ (Cárdenas-Navia et al, 2007). Finally, cyclic 
hypoxia is pervasive. As early as 1996, Kimura’s group (Kimura et al, 1996) measured 
microvessel red cell flux (RCF) and perivascular PO2 in xenotransplant of R3230Ac 
mammary carcinomas using intratumoral dorsal flap window chambers. They found that 
the baseline RCF and PO2 underwent a highly dynamic process, demonstrating that 
fluctuating hypoxia is a common phenomenon within a tumor. More recently, another 
group (Cárdenas-Navia et al, 2008) used phosphorescence lifetime imaging to detect 
fluctuation of vascular PO2 in rat fibrosarcomas, 9L gliomas and R3230 mammary 
adenocarcinomas transplanted in dorsal skin-fold window chambers. By short interval 
periodic imaging, they found O2 delivery to tumors is constantly instable. In addition, 
hypoxia, including acute and chronic hypoxia, causes genomic instability. Cyclic hypoxia 
mostly induces DNA double-strand breaks (DSBs) by generating reactive oxygen species 
(ROS). Chronic hypoxia causes genomic instability due to the defective HR ability. Thereby, 
both types of hypoxia facilitate mutagenesis leading to clonal selection with therapy-
resistant, invasive and metastatic phenotype (see Fig. 2).  
 
Fig. 2. Dynamic heterogeneity of hypoxia in solid tumor. Distinct hypoxia patterns exist in 
solid tumor. These patterns may overlap and co-exist in the same tumor bulk, which can be 
reflected though the 3D axis. Any point of this axis represents a combined type of hypoxia 
pattern in a tumor. 
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3.4.3 Hypoxic duration- and/or degree-related responses 
The existing status of oxygen level in tumor bulk is very heterogeneous, which is reflected 
by detected PO2 ranging from 0% to 100%, namely, from anoxia to normoxia. It is plausible 
that paradoxical activation of associated factors under hypoxia is also heterogeneous and 
dynamic in solid tumor, implying that focusing on one single target factor is insufficient to 
carry out an effective therapy. To date, although HIF-1ǂ has been comprehensively studied 
under different hypoxic conditions, it is not the case in the study of short period of severe 
hypoxia as well as chronic moderate hypoxia. This can be partially explained by the fact that 
regulation of HIF-1ǂ is actually a negative feedback loop via HIF-1ǂ-dependent induction of 
prolyl hydroxylase enzymes that promote the von Hippel-Lindau (VHL) tumour suppressor 
protein-mediated HIF-1ǂ degradation by ubiquitin-proteasome system under moderate 
hypoxia. On the contrary, the induction of prolyl hydroxylase enzymes is inhibited under 
severe hypoxia. Activation of eIF2ǂ has been indicated as a transient process during severe 
hypoxia, which is decreased following the prolonged duration of hypoxic status. Under 
moderate hypoxia, eIF2ǂ exhibits a gradually elevated activation along with elongation of 
hypoxic time.  
4. Role of cancer stem cells (CSCs) in hypoxia-induced therapeutic 
resistance in HNSCC  
4.1 Identification of CSCs in HNSCC 
The theory of CSCs, as a milestone of cancer research, has a history of 150 years. The focus 
of this theory is that there exists a sub-group of tumor cells, like stem cells of normal tissues, 
with stem traits characterizing growth stasis and self-renewal with specific cell surface 
markers. This subset of cells within the tumor bulk is known as “cancer stem cells” (CSCs) 
or “tumor initiating cells (TICs)”. Other tumor cells that are considered as progeny of CSCs 
would face a final differentiation followed by programmed cell death. In term of CSC 
theory, tumor bulk only originates from CSCs; therapeutic failures in cancer management 
are a result of insufficient elimination of these heterogeneous subpopulation. In addition, 
the subset is believed to play important roles in invasion, metastasis and therapeutic 
resistance in various malignancies. To date, CSCs or CSC like cells have been identified in 
different cancer including HNSCC. In 2007, a subpopulation of cells with characterized 
stemness and CD44 marker in HNSCC was first isolated and identified (Prince et al, 2007). It 
was also demonstrated that CD133+ cells in Hep-2 human squamous laryngeal carcinoma 
cells have stem cell-like characters (Zhou et al., 2009). Subsequently, other investigators 
identified a CD133+ CSC-like subset with chemoresistance in oral squamous carcinoma 
(Zhang et al., 2009). More recently, CD44+ CSCs have also been isolated and identified from 
human laryngeal squamous carcinoma. All these data confirm the existence of CSCs in 
HNSCC, which shed light on a novel area to get further insight into the mechanisms of 
chemo- and radioresistance in HNSCC with respect to SCCs. 
4.2 CSCs and microenvironment 
4.2.1 “Seeds and soil” theory 
The microenvironment of CSCs also called “niche”, consists of cellular and non-cellular 
components surrounding CSCs (Scadden, 2006), including direct cell contacts, cell-matrix 
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contacts, cytokines, blood vessels, mesenchymal cells and so on. It serves to protect CSCs 
from differentiation and apoptosis, and keeps the status of self-renewing (Iwasaki & Suda, 
2009). As a matter of fact, the significance of the niche function is far beyond these, as it 
affects the physiology of CSCs to a far more great extent. As early as 1889, through 
analysis of 735 cases of breast cancers, British assistant doctor Stephen Paget (Paget, 1989) 
found that breast cancer cells preferred liver to settle in rather than spleen that has 
vascular supply as abundant as liver. Nearly a century later, after the quiescence of the “ 
seeds and soils ”, Hart and Fidler (Hart & Fidler, 1980) injected melanoma cells into mice 
implanted with ovary tissue, kidney tissue and lung tissue in muscle or under the skin, 
and these implanted tissues had previously established vascular supplies of their own. 
Finally, they demonstrated that melanoma cells just metastasized to grafted ovary and 
kidney, suggesting that the formation of tumor is not only influenced by the characters of 
tumor cells but also depends on the niche. Because CSCs are a kind of cells that can self-
renew in malignancy, the niche of CSC must be critical for preserving the property of self-
renewal.  
Recently, many studies provided evidence for the “seeds and soil” even as they further 
disclosed the relationship between CSC and its niche. A group attenuated the adhesion 
between CSCs and some components of the niche, such as hyaluronan, through interfering 
with CD44, thereby, inhibited the neoplasia of myeloid leukemia (Jin et al, 2006; Krause et 
al, 2006). Calabrese et al (Calabrese et al, 2007) found that most medulloblastoma stem cells 
grew by adhering to endothelial cells selectively, and these CD133+ cells could give rise to 
new tumors only when co-transplanted with endothelial cells. Kaplan et al (Kaplan et al, 
2005) introduced a concept of “premetastatic niche”, which meant the microenvironment of 
metastasized organs had been induced to transform into a condition better for the formation 
of secondary tumor. All of the findings above suggest that targeting the niche will be a very 
significant approach to eliminate CSCs. 
4.2.2 Niche and heterogeneity 
Species are selected by adaptation to environmental changes as proven by the earliest 
dinosaurs to today’s diverse biological species. Such is Darwinian evolution, a possible 
explanation for survival. The development of tumors might be a process of survival of the 
fittest by the pressure of microenvironment. 
It is known to all that cells in various types of tumors are different from each other in many 
aspects, such as size, appearance, antigen expression, cell membrane composition and 
sensitivity to different treatment modalities (Ichim & Wells, 2006; Heppner, 1984; Axelson, 
2005). There are two explanatory models to the potential heterogeneity of the tumor cells, 
the stochastic model and the hierarchical model. Firstly, the stochastic model attributes the 
tumor development to the "genetic instability”, through which the ones best adapting to the 
microenvironment are selected to obtain the advantage of proliferation (Nowell, 1976; 
Tysnes & Bjerkvig, 2007). This model shows that the tumor parenchyma contains many 
types of tumor cells with the ability to form tumors in the microenvironment (Bjerkvig, 
2009). Secondly, the hierarchical model supports that the initial tumor and the metastatic 
tumor are both evolved from CSCs, which seems contradicting to the first model.  
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The two controversial models are currently interpreted by some recent investigations. 
Odoux et al (Odoux et al, 2008) found that a small number of CSCs subsets with the ability 
of self-renewal and differentiation exist in liver metastases in patients suffering from colon 
cancer, and this sub-group of cells are more invasive and expanding than the CSCs in the 
primary tumor. Surprisingly, as a considered decisive element in the evolution of tumor 
(Cahill et al, 2009), genetic instability was present in this subset. A recent genomics study 
found that aberrant stem cells significantly express the regulatory protein molecules which 
function to adapt to microenvironmental stimuli with respect to the gene expression profile 
of murine embryonic stem cell lines and its malignant counterpart, murine teratocarcinoma 
cell lines (Heffron, 2007). Campbell and Polyak (Campbell & Polyak, 2007) integrated the 
results of their research on breast cancer and a number of related reports, and ended up with 
that the heterogeneity of tumor cells may be due to the combination of some levels of the 
stochastic model and the hierarchical model. They found that the origin of breast cancer may 
initially be normal CD44-expression stem cells or progenitor cells, which undergo self-renewal, 
differentiation and mutation-driven clonal evolution motivated by the environmental changes 
and gene mutations, resulting in a bunch of different genotypes and diverse stages of 
development of tumor cells. This indicates that the hierarchical model in cancer stem cell 
theory is the extension of the stochastic model. Tumor tissues are evolved through genetic 
alterations, phenotypic changes and the impacts of micro-environment. So there may be more 
than one type of stem cell subsets with different characteristics in parenchyma, which exhibits 
different genetic or epigenetic phenotypes and ability to adapt to microenvironment, and the 
distinct characteristics of epithelial to mesenchymal transition (Werb & Evans, 2004). 
Therefore, not all CSCs have the ability to survive and metastasize, only those with the ability 
to adapt to the microenvironment are selected (Odoux, C et al, 2008; Lagasse, 2008) to do so. 
4.2.3 Hypoxia and CSCs 
As is known, CSCs are a subpopulation of tumor cells that co-exist with differentiated 
tumor cells in the same microenvironment, in which hypoxia serves as a necessary 
component for CSCs growth, self-renewal and differentiation (Keith & Simon, 2007). It has 
been demonstrated that HIF-1ǂ could induce the expression of some crucial genes related 
with CSCs’ self-renewal and multipotency, including Oct4 and Notch1. Under hypoxia, 
stable expression of HIF-1ǂ in CSCs can stimulate expressions of Oct4 and Notch1, and 
activate the associated signaling of critical pathways, promoting specific properties of CSCs 
and related multipotency. In view of the mentioned above, we can introduce the concept of 
interaction between tumor hypoxic microenvironment and CSCs. Traditionally, the 
standard for evaluating the efficacy of a treatment regimen is the sizable contraction of the 
tumor bulk. However, most tumor relapse after a period of paracmasis, probably because 
traditional chemo- and radiotherapy only kill tumor cells in rapid proliferation and 
differentiation rather than CSCs, the latter of which with are in slow divisions and 
proliferation, conferring therapeutic resistance. The formation of the relapsed tumor is 
driven by CSCs under proper microenvironment at a certain time after the treatment 
regimens are completed. 
4.2.4 CSC’s resistance and related mechanisms 
Lots of convincing data showed that CSCs subset displays powerful resistance to traditional 
chemo- and/or radio-therapy compared with non-CSCs of in same tumor or parent cells in 
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vitro. Currently, the mechanisms of CSCs-related therapeutic resistance have not been well 
understood. Perhaps, basic principles regarding CSC-caused therapeutic resistance can be 
categorized as follows.  
4.2.4.1 Quiescence 
Lots of cytotoxic drugs mostly kill tumor cells with rapid proliferation, which settle in 
cellular s-phase cycle. However, it is believed that CSCs, like normal stem cells, mostly 
reside in G0/G1 phase, which reduces efficacy of anti-cancer agents. 
4.2.4.2 Overexpression of protective genes  
Another cause of CSCs-related resistance is that this subset overexpresses some factors that 
protect CSCs from apoptosis and cytotoxicity. It has been well confirmed that CSCs express 
high levels of ABC drug transporters. Due to ATP hydrolysis, these proteins function to 
efflux drugs from tumor cells to protect against cytotoxicity. ABC superfamily includes 7 
subfamilies from ABCA to ABCG (ABCB1 is P-gp). Among the superfamily, ABCG2 has 
been studied most extensively and is believed to be the most critical transporter of drugs. 
However, in clinic, targeting on ABCG2 alone has a minimal effect in the correction of 
chemorisistance by cancers, suggesting other ABC components also participate in 
chemoresistance or CSC’s resistance is not determined only by ABC transporters. Liu et al  
(Liu et al, 2006) isolated CD133-positive tumor cells from glioblastoma and demonstrated 
that along with ABC transporters, these CSCs overexpressed anti-apoptotic factors, such as 
BCL-XL, Xiap, Survivin as well as cIAPs and DNA repair protein MGMT, which suggests 
that powerful repair ability combined with anti-apoptotic features may be  partially 
responsible for CSC’s resistance. Through studying CSCs from hepatocellular carcinoma 
(HCC), Ma et al (Ma et al, 2008) demonstrated that HCC CSCs confer chemorestistance via 
preferential induction of AKT/PKB and BCL-2 survival pathways. Using specific AKT1 
inhibitors, survival of HCC CSCs can be abolished.  
5. How to cope with the therapeutic resistance induced by hypoxia 
5.1 Targeting genes related with hypoxia 
Based on the mentioned above, it is evident that blockage of paradoxical activation of genes 
by transgenic techniques or improvement of hypoxic status in tumor microenvironment 
could overcome hypoxia-induced therapeutic resistance and relapse in HNSCC. Gene 
therapy mostly pointing to some critical target genes and associated gene products in HIF-
1ǂ, UPR and mTOR pathways and some activators and regulators of HIF-1ǂ in alternative 
pathways such as EGFR and STAT3 pathways offers hope in this regard. However, 
transgenic techniques using either viral or non-viral vectors have limitations for application 
in human body. As previously described, dynamic hypoxic heterogeneity exists in solid 
tumors. It is difficult to determine the specificity and effectiveness of a single-gene targeted 
therapy to hypoxic cells in a huge tumor bulk. Therefore, there should be a long-term 
exploration before gene therapy can be used as an efficient method of modifying therapeutic 
resistance in HNSCC. It is likely that a strategy targeting multiple genes would be a 
potential solution to CSC-associated therapeutic resistance under the condition that hypoxic 
status in each individual tumor is evaluated objectively.  
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5.2 Targeting CSCs and hypoxic microenvironment 
As stated, only CSCs can facilitate tumorigenesis and confer therapeutic resistance, which is 
the major cause of therapeutic failure. Therefore, successful targeting on CSCs is expected to 
provide a chance of cure for cancers. To date, targeting on CSCs has been faced with 
difficulties, because mechanisms underlying CSC-related therapeutic resistance have not 
been well understood. Although Notch, Oct-4, Wnt, Bmi and other stemness related factors 
were demonstrated to play a critical role in CSCs physiology, it is difficult to target them 
specifically in CSCs among the huge population of cancer cells. It is interesting to note that 
the clinical course of anti-ABCG-2 drugs in cancer treatment mirrors that of anti-bacterial 
agents in the control of infection. Based on this observation, some scholars believe that CSCs 
also experience evolutionary processes, and the driving force for these processes, selection 
stress by microenvironment, should be the target for cancer therapy. Although more CSCs 
markers have been identified in cancers, CSCs isolated by these markers are in minority, 
approximately 2-5%. However, increasing evidence has revealed that CSCs are not rare 
when isolated based on stem traits, which suggests that CSC markers are limited and not all 
CSCs express the same markers. Therefore, it is possible that CSCs are existing in separate 
subpopulations with distinct biological features, which are affected by their niche, and what 
is worse, these features are in constant change. Given that targeting CSCs is a putative 
approach, it would be much more important to concentrate on the manipulation of niche as 
the direct target in curing cancers. For example, we can resort to approaches to maintain the 
homeostasis of the niche by manipulating non-cellular components, especially fluctuating 
hypoxia. Consistent with this idea, traditional Chinese medicine (TCM) is to cure the disease 
by rectifying imbalance in body environment and re-establish the homeostasis of the human 
body, which may offer some hope in this regard. And intriguingly, lots of herbs have been 
identified as antioxidant compounds. Cai et al (Cai et al, 2004) have demonstrated that 112 
traditional chinese medicinal plants used as anti-cancer herbs have a more powerful 
antioxidant activity compared with common vegetables and fruits which are considered as 
good natural sources of dietary antioxidants. Tang et al (Tang et al, 2004) also identified the 
antioxidant function of TCM extracts. These pieces of evidence implicate that TCM is a 
promising strategy capable of targeting on ROS-induced evolution of CSCs.  Indeed, data 
from several reports have provided direct evidence that some herbs in TCM could target 
CSCs. Observations made by Jiang et al (Jiang et al, 1983) demonstrated that camptothecin 
and harringtonin could inhibit the clonal formation of human stem cells. Furthermore, anti-
tumor and therapeutic resistance-reversing effects of some phytochemicals such as 
Curcumin have been confirmed and proven to be prospective, which exhibit the capability 
of targeting side population cells (Fong et al, 2010). More recently, high inhibitory effect on 
breast cancer cells was acquired by combining stealthy liposomes from vinorelbine and 
parthenolide (Liu et al, 2008). Taken together, chemotherapy combined with TCM may 
dominate anti-cancer treatment if the niche is properly manipulated to overcome the 
chemoresisitance of CSCs resulting from genetic instability. 
5.3 Inducing UPR pro-death arms  
As is known, UPR is a double-edged sword. On the one side, it can help tumor cells relieve 
hypoxic stress； On the other hand, UPR can induce apoptosis or autophagy-related cell 
www.intechopen.com
Molecular Mechanisms Involving Therapeutic Resistance in Head and Neck Squamous  
Cell Carcinoma (HNSCC) – Roles of Hypoxic Microenvironment and Cancer Stem Cell 
 
227 
death under severe stress. Induction of UPR pro-death arms may be a promising modality 
to reverse hypoxia-induced resistance to traditional therapy. At this point, some agents, 
such as PIs, which can enhance ER overload, represent a promising perspective. PIs inhibit 
proteasome to reduce ERAD, which can intensify ER-stress caused by accumulation of 
unfolded protein. Recently, Fels et al (Fels et al, 2008) found that PIs can effectively enhance 
UPR responses of hypoxic tumor cells and ameliorating ER-stress can reverse PIs effects. 
They demonstrated that hypoxic tumor cells treated by PIs underwent apoptosis, autophagy 
and necrosis. Intriguingly, some groups reported that tumor cells can activate STAT3 to 
resist PIs therapy in HNSCC (C. Li et al, 2009). Therefore, PIs combined with STAT3 
inhibition could achieve potential efficiency. 
5.4 Chopping off hypoxia from the “root” 
For strategies used to improve local hypoxia, some groups have tried using inhalation of 
CarbogenȐ95%O2 and 5%CO2ȑand hyperbaric oxygen chambers to improve local hypoxic 
condition within tumors, and thus therapeutic resistance, but the results are not as 
satisfactory. In this regard, it is necessary to modify traditional approaches and to explore a 
new way of oxygen delivery to rectify the intratumoral hypoxic condition. It is a common 
sense that vascular structure of tumor is very different from its counterpart of normal tissue, 
the former of which exhibits architectural distortion, higher permeability and irregular 
infuse, facilitating fluctuating hypoxia and providing specific target strategy. Vascular 
disrupting agents (VDAs) serve as a novel type of anti-cancer target agent. In contrast with 
angiogenesis inhibitors (AIs) that mostly prevent neoformation of vascular structure, VDAs 
directly block or damage existing blood vessels in tumor bulk to commit necrosis. To date, 
VDAs have been in phase of clinic trails, and small molecular VDAs have been mostly 
studied. The mechanisms of VDAs action include: 1) induce TNF-ǂ secretion by tumor cells 
to cause apoptosis of endothelial cells constituting microvessels; 2) through binding to 
microtubule protein, VDAs facilitate disaggregation of microtubules to damage cell skeleton 
of vascular endothelium. VDAs have been believed to cause intratumoral necrosis, leaving 
the remaining periphery to be oxygenated. Therefore, combination of VDAs may cut both 
fluctuating and continuous hypoxia from the “boot”.   
Although improvement of tumor hypoxia has been achieved, imaging results are not always 
consistent with changes of endogenous markers of hypoxia, indicating that the 
improvement of intratumor hypoxia as observed by imaging does not represent the 
thorough rectification of intracellular hypoxic metabolisms of the cancer cells. Therefore, it 
is highly likely that there exist a “time gap” between improvement of intratumor hypoxia 
and thorough rectification of intracellular hypoxic metabolisms. Currently, length of this 
window phase is unclear. It is of paramount importance for hypoxic cells to gain thorough 
recovery of the intracellular oxygenation using this compensation time and become more 
susceptible to chemoratiation. 
6. Future directions 
Up till now, the impact of hypoxia on CSCs in HNSCC and its relation between chemo- and 
radiotherapeutic resistance is largely unknown. To further elucidate the causes of chemo- 
and radiotherapeutic resistance and post-treatment relapse in HNSCC with respect to effects 
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of tumor microenvironment on tumor cells, the first step is to study how hypoxic 
microenvironment regulates CSCs in HNSCC. Through establishment of HIF-1ǂ knock-
down cell lines (HIF-1ǂ-/-), the correlation between induction of HIF-1ǂ and related gene 
expressions associated with self-renewal as well as multipotency of CSCs is to be observed. 
Meanwhile, the differential expression of these genes between CD133+ and CD133- cells 
must be documented. Furthermore, the proliferative activity of CD133+ CSCs should be 
measured by culturing HIF-1ǂ+/+ and HIF-1ǂ-/- cells under normal or hypoxic conditions, 
thereby to understand whether hypoxic microenvironment modulates the differentiation 
and proliferation of CSCs by regulation of HIF-1ǂ in HNSCC.  
The established concept of interaction between tumor hypoxic microenvironment and CSCs 
helps us to further understand the mechanisms behind the therapeutic resistance in 
HNSCC. If CSCs are taken as anti-cancer targets, the strategies by focusing on tumor 
microenvironment will be promising for purposely intervention of CSCs (Iwasaki & Suda, 
2009). It can be inferred that CSCs are the critical element responsible for therapeutic 
resistance in HNSCC. Improving hypoxic conditions and regulating CSCs-related signaling 
pathways during chemo- and radiotherapy of HNSCC offers hope for reversion of 
therapeutic sensitivity in HNSCC and elimination of therapeutic resistance and relapse, 
aiming at improving outcomes of HNSCC.  
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